MEI Pharma Inc (MEIP) was Reiterated by Wedbush to “Neutral” while Lowering the Price Target of the company shares to $ 2 from a previous price target of $3 . Wedbush advised their investors in a research report released on Apr 18, 2016.
MEI Pharma Inc closed down -0.04 points or -2.44% at $1.6 with 11,27,189 shares getting traded on Friday. Post opening the session at $1.6, the shares hit an intraday low of $1.58 and an intraday high of $1.8 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
In a different news, on Jan 23, 2015, Charles V. Iii Baltic (director) purchased 5,000 shares at $3.81 per share price.
MEI Pharma Inc. is an oncology company. The Company is focused on the clinical development of drugs and therapies for treatment of cancer. The Company’s portfolio of clinical drug candidates includes Pracinostat ME-344 and PWT143. Pracinostat is an orally available histone deacetylase (HDAC) inhibitor indicated for the treatment of advanced hematologic diseases such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). ME-344 is an isoflavone-based mitochondrial inhibitor targeting a mitochondrial component of the terminal respiratory chain complex in rapidly proliferating cells. PWT143 is an oral inhibitor of phosphatidylinositide 3-kinase (PI3K) delta a molecular target that plays a critical role in the proliferation and survival of hematologic cancer cells. Pracinostat has been tested in multiple Phase I and Phase II clinical trials in advanced hematologic malignancies and solid tumor indications.